{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05450978",
            "orgStudyIdInfo": {
                "id": "STUDY21090138"
            },
            "secondaryIdInfos": [
                {
                    "id": "R01HD105305",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01HD105305"
                }
            ],
            "organization": {
                "fullName": "University of Pittsburgh",
                "class": "OTHER"
            },
            "briefTitle": "Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding",
            "officialTitle": "Physiological-based Pharmacokinetics Approach to Determine the Extent of Drug Exposure of Antiseizure Medications During Pregnancy and Breastfeeding",
            "acronym": "PBPK",
            "therapeuticArea": [
                "Women's Health",
                "Neurology"
            ],
            "study": "physiological-based-pharmacokinetics-approach-to-medication-exposure-during-pregnancy-and-breastfeeding"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-07-20",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-05-21",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-05-21",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-06-22",
            "studyFirstSubmitQcDate": "2022-07-06",
            "studyFirstPostDateStruct": {
                "date": "2022-07-11",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-16",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Page B. Pennell, MD",
                "investigatorTitle": "Professor",
                "investigatorAffiliation": "University of Pittsburgh"
            },
            "leadSponsor": {
                "name": "Page B. Pennell, MD",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This project focuses on anti-seizure medication (ASM) clearance and physiological factors determining blood concentrations in pregnant adult women with epilepsy and amounts of exposure to their unborn children and nursing infants.",
            "detailedDescription": "The goal of this study is to develop modeling of pharmacokinetic changes for Antiseizure medications (ASMs), lamotrigine (LTG), and levetiracetam (LEV) during pregnancy and postpartum that can be used to:\n\n1. Adjust doses in practice without obtaining frequent visits to the lab for therapeutic drug monitoring.\n2. Predict exposure of LTG and LEV in mothers and their infants in order to maintain the individualized target concentrations, thus protecting mothers from seizure worsening and minimizing fetal toxicity.\n\nHypotheses:\n\n1. Drug concentrations obtained in preconception and early pregnancy predict clearance changes throughout the remainder of pregnancy for individual pregnant women with epilepsy (WWE).\n2. Validated model allows the prediction of drug concentration changes at all stages throughout and after pregnancy, which will more accurately predict increased seizures and medication side effects."
        },
        "conditionsModule": {
            "conditions": [
                "Epilepsy",
                "Pregnancy Related"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": true,
            "targetDuration": "1 Year",
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "bioSpec": {
                "retention": "SAMPLES_WITH_DNA",
                "description": "Biological samples: blood, urine, breast milk, umbilical cord blood"
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Lamotrigine (LTG)",
                    "description": "Participants will include women with epilepsy planning pregnancy within the next 6 months and treated with lamotrigine (LTG)",
                    "interventionNames": [
                        "Drug: Lamotrigine"
                    ]
                },
                {
                    "label": "Levetiracetam (LEV)",
                    "description": "Participants will include women with epilepsy planning pregnancy within the next 6 months and treated with Levetiracetam (LEV)",
                    "interventionNames": [
                        "Drug: Levetiracetam"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Lamotrigine",
                    "description": "Anti-seizure concentrations",
                    "armGroupLabels": [
                        "Lamotrigine (LTG)"
                    ],
                    "otherNames": [
                        "Anti-seizure medication: Lamotrigine (LTG)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Levetiracetam",
                    "description": "Anti-seizure concentrations",
                    "armGroupLabels": [
                        "Levetiracetam (LEV)"
                    ],
                    "otherNames": [
                        "Anti-seizure medication: Levetiracetam (LEV)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Anti-Seizure Medication (ASM) Clearance",
                    "description": "ASM Clearance will be calculated from measurements of lamotrigine and levetiracetam blood concentrations, serum creatinine and 24-hour urine collection (for levetiracetam), glucuronidated metabolite (for lamotrigine), steroid hormones, medication formulation and doses, time since recent doses, and participant weight.",
                    "timeFrame": "Through study completion, an average of 18 months."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Seizure Frequency",
                    "description": "Participants will keep a daily seizure diary throughout their participation in the study. The diary will be reviewed at each study visit.",
                    "timeFrame": "Through study completion, an average of 18 months."
                },
                {
                    "measure": "Anti-seizure Medication (ASM) Side Effects",
                    "description": "An ASM Side Effect Questionnaire will be administered and a neurologic examination will be performed at each study visit.",
                    "timeFrame": "Through study completion, an average of 18 months"
                },
                {
                    "measure": "Placental passage of Anti-Seizure Medications (ASM)",
                    "description": "Maternal blood will be drawn and umbilical cord blood will be collected, for measurements of ASM concentrations for lamotrigine and levetiracetam.",
                    "timeFrame": "Through study completion, an average of 18 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Women planning pregnancy within the next 6 months.\n* Women currently being treated with lamotrigine (LTG) or levetiracetam (LEV) for a diagnosis of epilepsy\n\nExclusion Criteria:\n\n* History of psychogenic non-epileptic spells\n* History of other major medical illnesses including renal or hepatic disease, progressive cerebral disease,\n* Inability to maintain a seizure and medication daily diary\n* Present or recent history of drug or alcohol abuse, or the use of any concomitant medications that interact with the ASM they are taking (lamotrigine or levetiracetam).",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "genderBased": true,
            "genderDescription": "Women with Epilepsy",
            "minimumAge": "14 Years",
            "maximumAge": "45 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ],
            "studyPopulation": "Participants to be mainly recruited from Epilepsy and OBGYN clinics.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Nikhil Khongbantabam, BS",
                    "role": "CONTACT",
                    "phone": "4125924018",
                    "email": "nik66@pitt.edu"
                },
                {
                    "name": "Erica Kemp, PA",
                    "role": "CONTACT",
                    "email": "kempe2@upmc.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Page B Pennell, MD",
                    "affiliation": "The University of Pittsburgh",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Kaufmann Medical Building",
                    "status": "RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15213",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Nikhil Khongbantabam, BS",
                            "role": "CONTACT",
                            "phone": "412-592-4018",
                            "email": "nik66@pitt.edu"
                        },
                        {
                            "name": "Erica Kemp, PA",
                            "role": "CONTACT",
                            "email": "kempe2@upmc.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "33369356",
                    "type": "BACKGROUND",
                    "citation": "Pennell PB, French JA, May RC, Gerard E, Kalayjian L, Penovich P, Gedzelman E, Cavitt J, Hwang S, Pack AM, Sam M, Miller JW, Wilson SH, Brown C, Birnbaum AK, Meador KJ; MONEAD Study Group. Changes in Seizure Frequency and Antiepileptic Therapy during Pregnancy. N Engl J Med. 2020 Dec 24;383(26):2547-2556. doi: 10.1056/NEJMoa2008663."
                },
                {
                    "pmid": "31886825",
                    "type": "BACKGROUND",
                    "citation": "Birnbaum AK, Meador KJ, Karanam A, Brown C, May RC, Gerard EE, Gedzelman ER, Penovich PE, Kalayjian LA, Cavitt J, Pack AM, Miller JW, Stowe ZN, Pennell PB; MONEAD Investigator Group. Antiepileptic Drug Exposure in Infants of Breastfeeding Mothers With Epilepsy. JAMA Neurol. 2020 Apr 1;77(4):441-450. doi: 10.1001/jamaneurol.2019.4443."
                },
                {
                    "pmid": "35157004",
                    "type": "BACKGROUND",
                    "citation": "Pennell PB, Karanam A, Meador KJ, Gerard E, Kalayjian L, Penovich P, Matthews A, McElrath TM, Birnbaum AK; MONEAD Study Group. Antiseizure Medication Concentrations During Pregnancy: Results From the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study. JAMA Neurol. 2022 Apr 1;79(4):370-379. doi: 10.1001/jamaneurol.2021.5487."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED",
            "description": "We will adhere to the NIH Grants Policy Statement on Sharing of Biomedical Research Resources, including the \"Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources: Final Notice.\" The results of the studies proposed here will be shared with the scientific community on a regular basis through presentations at scientific meetings and peer-reviewed publications in appropriate scientific journals. Any material resources developed as a result of this grant will be made available to other investigators once a Material Transfer Agreement has been signed between the University of Minnesota and the requesting investigator's institution."
        }
    },
    "documentSection": {
        "largeDocumentModule": {
            "largeDocs": [
                {
                    "typeAbbrev": "Prot",
                    "hasProtocol": true,
                    "hasSap": false,
                    "hasIcf": false,
                    "label": "Study Protocol",
                    "date": "2022-02-25",
                    "uploadDate": "2022-05-14T09:33",
                    "filename": "Prot_000.pdf",
                    "size": 162823
                },
                {
                    "typeAbbrev": "ICF",
                    "hasProtocol": false,
                    "hasSap": false,
                    "hasIcf": true,
                    "label": "Informed Consent Form",
                    "date": "2022-06-10",
                    "uploadDate": "2022-06-22T11:31",
                    "filename": "ICF_001.pdf",
                    "size": 641309
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000004827",
                    "term": "Epilepsy"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7983",
                    "name": "Epilepsy",
                    "asFound": "Epilepsy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077213",
                    "term": "Lamotrigine"
                },
                {
                    "id": "D000077287",
                    "term": "Levetiracetam"
                },
                {
                    "id": "D000000927",
                    "term": "Anticonvulsants"
                }
            ],
            "ancestors": [
                {
                    "id": "D000018697",
                    "term": "Nootropic Agents"
                },
                {
                    "id": "D000002121",
                    "term": "Calcium Channel Blockers"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000077264",
                    "term": "Calcium-Regulating Hormones and Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000014150",
                    "term": "Antipsychotic Agents"
                },
                {
                    "id": "D000014149",
                    "term": "Tranquilizing Agents"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000011619",
                    "term": "Psychotropic Drugs"
                },
                {
                    "id": "D000026941",
                    "term": "Sodium Channel Blockers"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1741",
                    "name": "Levetiracetam",
                    "asFound": "Activated",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1701",
                    "name": "Lamotrigine",
                    "asFound": "Resin",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4246",
                    "name": "Anticonvulsants",
                    "asFound": "Resin",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20774",
                    "name": "Nootropic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M5384",
                    "name": "Calcium Channel Blockers",
                    "relevance": "LOW"
                },
                {
                    "id": "M5381",
                    "name": "Calcium",
                    "relevance": "LOW"
                },
                {
                    "id": "M5398",
                    "name": "Calcium, Dietary",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M16904",
                    "name": "Antipsychotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M14474",
                    "name": "Psychotropic Drugs",
                    "relevance": "LOW"
                },
                {
                    "id": "M23177",
                    "name": "Sodium Channel Blockers",
                    "relevance": "LOW"
                },
                {
                    "id": "M30025",
                    "name": "Diuretics, Potassium Sparing",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AntiConv",
                    "name": "Anticonvulsants"
                },
                {
                    "abbrev": "NootAg",
                    "name": "Nootropic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ChanBlk",
                    "name": "Channel Blockers"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                },
                {
                    "abbrev": "BDCA",
                    "name": "Bone Density Conservation Agents"
                }
            ]
        }
    },
    "hasResults": false
}